The Effect of Perioperative Administration of Treprostinil in Infants with Non-restrictive Ventricular Septal Defect and Severe Pulmonary Arterial Hypertension

Pediatr Cardiol. 2020 Oct;41(7):1334-1339. doi: 10.1007/s00246-020-02387-y. Epub 2020 May 28.

Abstract

This study investigated the efficacy and safety of intravenous treprostinil during the perioperative period in infants with non-restrictive ventricular septal defect (VSD) and severe pulmonary arterial hypertension (PAH) undergoing surgical VSD repair. This was a retrospective study. There were 79 infants with non-restrictive VSD and severe PAH receiving surgical treatment from January to December 2019 in our cardiac center. The patients were divided into the treprostinil group and control group according to whether intravenous treprostinil was used during the perioperative period. There were no significant differences in the preoperative characteristics, including age, sex, weight, ventricular size, or preoperative pulmonary artery pressure, between the two groups. Although the pulmonary artery pressure in both groups was significantly lower postoperatively than preoperatively, the postoperative pulmonary artery systolic pressure was significantly lower in group T than in group C. The postoperative mechanical ventilation time, ICU stay, and hospital stay in group T were shorter than those in group C. Treprostinil can be used effectively and safely to reduce the perioperative pulmonary artery pressure in infants with non-restrictive VSD and severe PAH undergoing surgical VSD repair.

Keywords: Infant; Perioperative administration; Pulmonary arterial hypertension; Treprostinil.

MeSH terms

  • Administration, Intravenous
  • Antihypertensive Agents / administration & dosage*
  • Antihypertensive Agents / adverse effects
  • Epoprostenol / administration & dosage
  • Epoprostenol / adverse effects
  • Epoprostenol / analogs & derivatives*
  • Female
  • Heart Septal Defects, Ventricular / complications
  • Heart Septal Defects, Ventricular / drug therapy*
  • Heart Septal Defects, Ventricular / surgery*
  • Heart Ventricles / physiopathology
  • Humans
  • Infant
  • Length of Stay
  • Male
  • Perioperative Period
  • Pulmonary Arterial Hypertension / complications
  • Pulmonary Arterial Hypertension / drug therapy*
  • Pulmonary Arterial Hypertension / surgery
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome

Substances

  • Antihypertensive Agents
  • Epoprostenol
  • treprostinil